Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
|Articles|November 22, 1995

MCD propels new ADAC technology

Nuclear medicine vendor ADAC Laboratories will highlight its MolecularCoincidence Detection (MCD) technique, which enables high-energypositron imaging to be conducted on gamma cameras without theuse of the heavy collimators employed in 511-KeV imaging.

Nuclear medicine vendor ADAC Laboratories will highlight its MolecularCoincidence Detection (MCD) technique, which enables high-energypositron imaging to be conducted on gamma cameras without theuse of the heavy collimators employed in 511-KeV imaging.

ADAC, of Milpitas, CA, debuted MCD at the Society of NuclearMedicine meeting in Minneapolis earlier this year (SCAN 6/21/95).By employing the digital architecture of ADAC's Epic technology,MCD uses electronic collimation to measure coincidents, whichoccur when photons are released at 180° angles due to theannihilation of an electron by a positron. MCD achieves an intrinsicresolution of 4 mm, compared to about 10-mm resolution in 511-KeVimaging. ADAC is awaiting 510(k) clearance for the technique.

ADAC's Solus and Cardio gamma cameras will also make their RSNAdebut. Introduced at the SNM meeting, Solus is a fixed-angle 180°dual-head camera, while Cardio is a 90° dual-head for dedicatedcardiac imaging. The new products are designed to target specificapplications at a lower price point than ADAC's premium Vertexcamera.

The third part of ADAC's new product triangle is Vantage, thevendor's attenuation-correction protocol for cardiac imaging,which received Food and Drug Administration clearance in April(SCAN 5/10/95).


Related to this article

Emerging Research Insights and New Advances in Neuroradiology
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.